Cochlear
Cochlear Limited is an Australian medical device company that designs, manufactures, and distributes implantable hearing solutions globally. The company produces cochlear implants, acoustic implants, bone conduction systems, sound processors, and wireless accessories designed to address moderate to profound hearing loss. Primary revenues are generated from the sale of implant systems, sound processor upgrades, replacement parts, and clinical support services. Cochlear serves audiologists, ENT surgeons, healthcare institutions, and hearing-impaired patients across North America, Europe, Asia-Pacific, and emerging markets. The enterprise holds a dominant global market position in the implantable hearing device sector, holding significant market share worldwide. Cochlear Limited is headquartered in Sydney, Australia, and its common shares are listed on the Australian Securities Exchange.
17 of the funds FundTelligence covers report a position in Cochlear.
- Legal name
- Cochlear Ltd.
- Sector
- Health Care
- Country
- Australia
- Funds holding it
- 17
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Hearing
Funds holding Cochlear
- Schroder ISF Asian Equity Yield — Schroders · 1.1 % (full portfolio disclosed, June 2026)
- Schroder ISF Asian Total Return — Schroders · 0.66 % (full portfolio disclosed, June 2026)
- Lannebo Marknad Pacific — Lannebo · 0.46 % (full portfolio disclosed, June 2026)
- Danske Invest Index Pacific incl. Canada ex. Japan Restricted — Danske Invest · 0.3 % (full portfolio disclosed, July 2026)
- KLP AksjeAsia Indeks — KLP · 0.08 % (full portfolio disclosed, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)
- Handelsbanken Utviklede Markeder Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- Lannebo Marknad Global — Lannebo · 0.02 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 17 funds holding it.